Literature DB >> 1624158

Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease.

M Z Mazlam1, H J Hodgson.   

Abstract

Cytokines released from activated mononuclear leukocytes are involved in triggering the acute phase response and many of the inflammatory manifestations of ulcerative colitis and Crohn's disease. The ability of circulating monocytes from patients with ulcerative colitis and Crohn's disease to generate the cytokines interleukin 1 beta (IL 1 beta) and tumour necrosis factor alpha (TNF alpha), both spontaneously and in response to stimulation by lipopolysaccharide, was compared. IL 1 beta generation in response to lipopolysaccharide was significantly higher in Crohn's disease than in ulcerative colitis and normal controls, with a dramatic increase in patients with active disease. There was a significant reduction in lipopolysaccharide stimulated TNF alpha generation in ulcerative colitis patients compared with Crohn's disease and normal control subjects. IL 1 beta and TNF alpha release correlated significantly with serum C reactive protein and serum alpha 1 acid glycoprotein in Crohn's disease. The ability of conditioned medium from monocytes in Crohn's disease to enhance release of alpha 1 acid glycoprotein from the liver cell line HepG2 in culture was assessed. There was a significant positive correlation between TNF alpha and IL 1 beta presence in the supernatant and alpha 1 acid glycoprotein production. The differences in the cytokine profile in patients with Crohn's disease compared with ulcerative colitis suggest an intrinsic difference in the ability to produce cytokines in patients with these two forms of inflammatory bowel disease, and may explain features such as the enhanced ability to generate a brisk C reactive protein response in Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1624158      PMCID: PMC1379334          DOI: 10.1136/gut.33.6.773

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  37 in total

1.  Hepatocyte-stimulating factor.

Authors:  B M Woloski; G M Fuller
Journal:  Methods Enzymol       Date:  1988       Impact factor: 1.600

2.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

Authors:  J Gauldie; C Richards; D Harnish; P Lansdorp; H Baumann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

Review 3.  Hepatic acute phase reaction in vivo and in vitro.

Authors:  H Baumann
Journal:  In Vitro Cell Dev Biol       Date:  1989-02

Review 4.  The interleukins.

Authors:  S B Mizel
Journal:  FASEB J       Date:  1989-10       Impact factor: 5.191

Review 5.  Tumour necrosis factor.

Authors:  F R Balkwill
Journal:  Br Med Bull       Date:  1989-04       Impact factor: 4.291

6.  T cell-mediated production of tumour necrosis factor-alpha by monocytes.

Authors:  J M Debets; C J van der Linden; I E Spronken; W A Buurman
Journal:  Scand J Immunol       Date:  1988-05       Impact factor: 3.487

7.  Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings.

Authors:  H R Michie; D R Spriggs; K R Manogue; M L Sherman; A Revhaug; S T O'Dwyer; K Arthur; C A Dinarello; A Cerami; S M Wolff
Journal:  Surgery       Date:  1988-08       Impact factor: 3.982

8.  Action of recombinant human interleukin 6, interleukin 1 beta and tumor necrosis factor alpha on the mRNA induction of acute-phase proteins.

Authors:  T Andus; T Geiger; T Hirano; T Kishimoto; P C Heinrich
Journal:  Eur J Immunol       Date:  1988-05       Impact factor: 5.532

9.  Heterogeneous nature of the acute phase response. Differential regulation of human serum amyloid A, C-reactive protein, and other acute phase proteins by cytokines in Hep 3B cells.

Authors:  M K Ganapathi; D Schultz; A Mackiewicz; D Samols; S I Hu; A Brabenec; S S Macintyre; I Kushner
Journal:  J Immunol       Date:  1988-07-15       Impact factor: 5.422

10.  Serum amyloid A protein compared with C-reactive protein, alpha 1-antichymotrypsin and alpha 1-acid glycoprotein as a monitor of inflammatory bowel disease.

Authors:  R E Chambers; P Stross; R E Barry; J T Whicher
Journal:  Eur J Clin Invest       Date:  1987-10       Impact factor: 4.686

View more
  28 in total

1.  Enhanced production of IL-8 in chronic but not in early ileal lesions of Crohn's disease (CD).

Authors:  E Brandt; J F Colombel; N Ectors; L Gambiez; D Emilie; K Geboes; M Capron; P Desreumaux
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

2.  IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease.

Authors:  C Gasche; S Bakos; C Dejaco; W Tillinger; S Zakeri; W Reinisch
Journal:  J Clin Immunol       Date:  2000-09       Impact factor: 8.317

3.  In vitro production of TNF-alpha,IL-6 and sIL-2R in Chinese patients with ulcerative colitis.

Authors:  Bing Xia; Hai-Jian Guo; JBA Crusius; Chang-Sheng Deng; SGM Meuwissen; AS Pena
Journal:  World J Gastroenterol       Date:  1998-06       Impact factor: 5.742

4.  Synergistic effect of immunoregulatory cytokines on peripheral blood monocytes from patients with inflammatory bowel disease.

Authors:  T Kucharzik; N Lügering; M Adolf; W Domschke; R Stoll
Journal:  Dig Dis Sci       Date:  1997-04       Impact factor: 3.199

5.  Genetic markers in clinically well defined patients with ulcerative colitis (UC).

Authors:  G Bouma; J B Crusius; M A García-González; B U Meijer; H P Hellemans; R J Hakvoort; G M Schreuder; P J Kostense; S G Meuwissen; A S Peña
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

6.  Cytokine messenger RNA expression and proliferation status of intestinal mononuclear cells in noninflamed gut and Crohn's disease.

Authors:  F Autschbach; G Schürmann; L Qiao; H Merz; R Wallich; S C Meuer
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

7.  Significance of systemic endotoxaemia in inflammatory bowel disease.

Authors:  K R Gardiner; M I Halliday; G R Barclay; L Milne; D Brown; S Stephens; R J Maxwell; B J Rowlands
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

8.  Osteoporosis and determinants of bone density in patients with Crohn's disease.

Authors:  R J Robinson; F al-Azzawi; S J Iqbal; T Kryswcki; L Almond; K Abrams; J F Mayberry
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

9.  Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease.

Authors:  M Z Mazlam; H J Hodgson
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

10.  Human colon carcinomas constitutively express and shed type II IL-1 receptor, an IL-1 antagonist.

Authors:  Andrew W Stadnyk; Moorix M W Yeung; Sen Rong Yan
Journal:  Dig Dis Sci       Date:  2003-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.